Related Experiment Video
Updated: Aug 21, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Enterococcus faecalis resistant to linezolid: case series and review of the literature
Brian S Burleson1, David J Ritchie, Scott T Micek
1Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Abstract:
Reports of linezolid resistance among Enterococcus faecalis have been relatively rare. We describe three patients with linezolid-resistant strains of E. faecalis, discovered after the patients had received long courses (> 30 days) of linezolid therapy. All strains contained the G2576U mutation in 23S rRNA. A literature review revealed one other case in the United States and three cases in Europe; all involved patients who had received long courses of therapy. It appears that recent or extended linezolid therapy may be a risk factor for development of resistant E. faecalis. In patients who have recently been treated with linezolid and have an identified new systemic enterococcal isolate, linezolid sensitivity should be verified as soon as possible to guide therapy. This strategy also should be considered for patients with a breakthrough enterococcal isolate during linezolid therapy.
Insights
Reports of linezolid resistance in Enterococcus faecalis are rare but linked to extended linezolid therapy. This study identified three cases, highlighting the need to verify linezolid sensitivity in patients with recent or prolonged treatment.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Linezolid is a crucial antibiotic for treating infections caused by Gram-positive bacteria, including resistant strains.
- Reports of linezolid resistance in Enterococcus faecalis have been infrequent, making emerging resistance a significant concern.
Observation:
- Three patients developed linezolid-resistant Enterococcus faecalis after prolonged (>30 days) linezolid treatment.
- All resistant strains harbored the G2576U mutation in the 23S rRNA gene.
- A literature review identified additional cases in the US and Europe, all associated with extended linezolid therapy.
Findings:
- Extended or recent linezolid therapy appears to be a risk factor for the development of linezolid-resistant Enterococcus faecalis.
- The G2576U mutation in 23S rRNA is associated with linezolid resistance in these strains.
Implications:
- Clinicians should verify linezolid sensitivity in patients with new systemic enterococcal isolates who have recently undergone linezolid therapy.
- Monitoring for linezolid resistance is crucial in patients experiencing breakthrough enterococcal infections during linezolid treatment.
- This underscores the importance of judicious antibiotic use and resistance surveillance.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
